Advancing Tropical Medicine: Interdisciplinary Approaches, Innovation, and Health System Strengthening

Year : 2024 | Volume :01 | Issue : 02 | Page : 1-13
By

Satish Kumar Sarankar

Sushma Somkuwar

Abstract

Tropical medicine encompasses a diverse range of infectious diseases prevalent in tropical and subtropical regions, presenting complex challenges to global health. This review offers an extensive examination of critical aspects within tropical medicine, emphasizing recent progress and upcoming avenues of research. Interdisciplinary collaboration is highlighted as essential for addressing the multifaceted nature of tropical diseases, with healthcare professionals, veterinarians, ecologists, epidemiologists, and social scientists working together to tackle complex health challenges. Innovation in diagnostics and therapeutics, including the development of rapid diagnostic tests and novel treatment strategies, is crucial for improving disease surveillance, case management, and outbreak response. Vector control and environmental management strategies, integrated within the framework of One Health approaches, play a pivotal role in reducing the burden of vector-borne diseases in tropical regions. Additionally, strengthening health systems through infrastructure development, workforce capacity building, and research translation is imperative for improving access to quality healthcare and public health services. By addressing these key areas and investing in collaborative research and intervention efforts, we can advance the prevention, control, and management of tropical diseases and improve health outcomes for populations in tropical regions and beyond.

Keywords: Tropical diseases, vector control, global health, antimicrobial resistance, infectious diseases, epidemiology

[This article belongs to International Journal of Tropical Medicines(ijtm)]

How to cite this article: Satish Kumar Sarankar, Sushma Somkuwar. Advancing Tropical Medicine: Interdisciplinary Approaches, Innovation, and Health System Strengthening. International Journal of Tropical Medicines. 2024; 01(02):1-13.
How to cite this URL: Satish Kumar Sarankar, Sushma Somkuwar. Advancing Tropical Medicine: Interdisciplinary Approaches, Innovation, and Health System Strengthening. International Journal of Tropical Medicines. 2024; 01(02):1-13. Available from: https://journals.stmjournals.com/ijtm/article=2024/view=144957





References

  1. Downs P, Bush S, Bannerman R et al. Neglected tropical disease elimination is a relay race — let’s not drop the baton. Int Health. 2022;14(Suppl 2):ii1–ii6.
  2. Kotloff KL, Nataro JP, Blackwelder JC, et al. Burden and aetiology of diarrhoeal disease in infants and young children in developing countries (the Global Enteric Multicenter Study, GEMS): a prospective, case-control study. Lancet. 2013;382:209–222.
  3. Molyneux DH. The ‘Neglected Tropical Diseases’: Now a brand identity, responsibilities, context and promise. Parasites Vectors. 2012;5. doi: 10.1186/1756-3305-5-23.
  4. World Health Organization. Report of the first meeting of the WHO Diagnostic Technical Advisory Group for Neglected Tropical Diseases Geneva, 30–31 October 2019. Geneva: World Health Organization; 2020.
  5. Bangert M, Molyneux DH, Lindsay SW et al. The cross-cutting contribution of the end of neglected tropical diseases to the sustainable development goals. Infect Dis Poverty. 2017;6(1):73.
  6. Heymann DL, Dixon M. Infections at the animal/human interface: shifting the paradigm from emergency response to prevention at source. Curr Top Microbiol Immunol. 2013;366:207–215.
  7. Cowman A, Healer J, Marapana D, Marsh K. Malaria, Biology and Disease. Cell. 2016;167:610–624.
  8. World Health Organization. Global Report on Insecticide Resistance in Malaria Vectors, 2010–2016. WHO; Geneva, Switzerland: 2018.
  9. Callender DM. Management and control of yellow fever virus: Brazilian outbreak January-April, 2018. Glob Public Health. 2019 Mar;14(3):445-455.
  10. Rachman A, Harahap AR, Widhyasih RM. The role of anti-dengue virus NS-1 and anti-protein disulfide isomerase antibodies on platelet aggregation in secondary dengue infection. Acta Med Indones. 2013;45(1):44–48.
  11. Foley JA, Defries R, Asner GP, Barford C, Bonan G, Carpenter SR, et al. Global consequences of land use. Science. 2005;309:570–574.
  12. Unnasch TR, Golden A, Cama V, Cantey PT. Diagnostics for onchocerciasis in the era of elimination. Int Health. 2018 Mar 01;10(suppl_1):i20-i26.
  13. Neil S, Bieniasz P. Human immunodeficiency virus, restriction factors, and interferon. J Interferon Cytokine Res. 2009;29:569–580.
  14. Nabudere H, Upunda GL, Juma M. Policy brief on improving access to artemisinin-based combination therapies for malaria in the East African community. Int J Technol Assess Health Care. 2010;26:255–259.
  15. Glasner DR, Puerta-Guardo H, Beatty PR, Harris E. The good, the bad, and the shocking: the multiple roles of dengue virus nonstructural protein 1 in protection and pathogenesis. Annu Rev Virol. 2018;5(1):227–253.
  16. Weil AA, Ryan ET. Cholera: recent updates. Curr Opin Infect Dis. 2018 Oct;31(5):455-461.
  17. Gharbaran R, Somenarain L. Putative Cellular and Molecular Roles of Zika Virus in Fetal and PediatricNeuropathologies. Pediatr Dev Pathol. 2019 Jan-Feb;22(1):5-21.
  18. Chen LH, Kozarsky PE, Visser LG. What’s Old Is New Again: The Re-emergence of Yellow Fever in Brazil and Vaccine Shortages. Clin Infect Dis. 2019 May 02;68(10):1761-1762.
  19. Hotez PJ, Dumonteil E, Heffernan MJ, Bottazzi ME. Innovation for the “bottom 100 million”: eliminating neglected tropical diseases in the Americas. Adv Exp Med Biol. 2013;764:1–12.
  20. Takada A, Feldmann H, Ksiazek TG, Kawaoka Y. Antibody-dependent enhancement of Ebola virus infection. J Virol. 2003;77(13):7539–7544.
  21. Mogasale V, Maskery B, Ochiai RL, et al. Burden of typhoid fever in low-income and middle-income countries: a systematic, literature-based update with risk-factor adjustment. Lancet Glob Health. 2014;2:e570–e580.
  22. Wattal C, Goel N. Infectious disease emergencies in returning travelers: special reference to malaria, dengue fever, and chikungunya. Med Clin North Am. 2012;96:1225–1255.
  23. Shehu NY, Shwe D, Onyedibe KI, Pam VC, Abok I, Isa SE, Egah DZ. Pathogenesis, diagnostic challenges and treatment of zika virus disease in resource-limited settings. Niger Postgrad Med J. 2018 Apr-Jun;25(2):67-72.
  24. Kitchen LW, Lawrence KL, Coleman RE. The role of the United States military in the development of vector control products, including insect repellents, insecticides, and bed nets. J Vector Ecol. 2009;34(1):50–61.
  25. Oxborough RM. Trends in US President’s Malaria Initiative-funded indoor residual spray coverage and insecticide choice in sub-Saharan Africa (2008–2015): urgent need for affordable, long-lasting insecticides. Malar J. 2016;15(1):146.
  26. White MT, Griffin JT, Churcher TS, Ferguson NM, Basáñez MG, Ghani AC. Modelling the impact of vector control interventions on Anopheles gambiae population dynamics. Parasit Vectors. 2011;4:153.
  27. Karunamoorthi K. Malaria vaccine, a future hope to curtail the global malaria burden. Int J Prev Med. 2014;5:529–538.
  28. Mammen MP, Lyons A, Innis BL, Sun W, McKinney D, Chung RCY, et al. Evaluation of dengue virus strains for human challenge studies. Vaccine. 2014;32(13):1488–1494.
  29. Bethony JM, Cole RN, Guo X, Kamhawi S, Lightowlers MW, Loukas A, Petri W, Reed S, Valenzuela JG, Hotez PJ. Vaccines to combat the neglected tropical diseases. Immunol Rev. 2011;239:237–270.
  30. Hotez PJ, Brown AS. Neglected tropical disease vaccines. Biologicals. 2009;37:160–164.
  31. Thomas SJ, Endy TP. Critical issues in dengue vaccine development. Curr Opin Infect Dis. 2011;24:442–450.
  32. Hotez P. A handful of ‘antipoverty’ vaccines exist for neglected diseases, but the world’s poorest billion people need more. Health Affairs. 2011;30:1080–1087.
  33. Sears A.V., Hay R.J. Buruli ulcer—A rapidly changing scene. Acta Derm. Venereol. 2015;95:387–388.
  34. Meshnick S.R., Dobson M.J. The History of Antimalarial Drugs. In: Rosenthal P., editor. Antimalarial Chemotherapy, Mechanisms of Action, Resistance, and New Directions in Drug Discovery. Humana Press; Totowa NJ, USA: 2001. p. 396.
  35. Lynch JB. Multidrug-resistant tuberculosis. Med Clin North Am. 2013;97:553–557.
  36. Chowdhury R., Mondal D., Chowdhury V., Faria S., Alvar J., Nabi S.G., Boelaert M., Dash A.P. How far are we from visceral leishmaniasis elimination in Bangladesh? An assessment of epidemiological surveillance data. PLoSNegl. Trop. Dis. 2014;8:e3020.
  37. Njogu PM, Chibale K. Recent developments in rationally designed multitarget antiprotozoan agents. Curr Med Chem. 2013;20:1715–1742.
  38. Olsen A. Efficacy and safety of drug combinations in the treatment of schistosomiasis, soil-transmitted helminthiasis, lymphatic filariasis and onchocerciasis. Trans R Soc Trop Med Hyg. 2007;101:747–758.
  39. Lashley FR. Emerging infectious diseases: vulnerabilities, contributing factors and approaches. Expert Rev Anti Infect Ther. 2004;2:299–316.
  40. Mrazek M. Stimulating pharmaceutical research and development for neglected diseases Health Policy. 2003;64:75–88.
  41. Ngwa MC, Liang S, Mbam LM, Mouhaman A, Teboh A, Brekmo K, Mevoula O, Morris JG. Cholera public health surveillance in the Republic of Cameroon-opportunities and challenges. Pan Afr Med J. 2016;24:222.
  42. UN News Centre. Ebola: UN health agency says more than 1 million people affected by outbreak. 2014.
  43. Heymann DL. Control, elimination, eradication and re-emergence of infectious diseases: getting the message right. Bull. World Health Organ. 2006;84:82.
  44. Interagency meeting on planning the prevention and control of neglected zoonotic diseases (NZDs), Geneva, 5-6 July 2011. Geneva, Switzerland: WHO; 2011.
  45. Paphitou NI. Antimicrobial resistance: action to combat the rising microbial challenges. Int. J. Antimicrob. Agents. 2013;42(Suppl):S25–S28.
  46. Hepp SL, Suter E, Jackson K, et al. Using an interprofessional competency framework to examine collaborative practice. J Interprof Care. 2015;29(2):131-137.
  47. Norby B. Healthcare students as innovative partners in the development of future healthcare services: An action research approach. Nurse Educ Today. 2016;46:4–9.
  48. World Health Organization—Vector Control Advisory Group. Overview of intervention classes and prototype/products under Vector Control Advisory Group (VCAG) review for assessment of public health value (as of 09 May 2019). Geneva: World Health Organization; 2019.
  49. Shrestha K, Acharya K.P, Shrestha S. One Health:The interface between veterinary and human health. Int J One Health. 2018;4(1):8–14.
  50. Lennox L, Maher L, Reed J. Navigating the sustainability landscape: a systematic review of sustainability approaches in healthcare. Impl Sci. 2018;13(1):1–17.

Regular Issue Subscription Review Article
Volume 01
Issue 02
Received April 10, 2024
Accepted April 18, 2024
Published May 4, 2024